SURVIVAL ANALYSIS OF PATIENTS DIAGNOSED WITH METASTATIC PROSTATE CANCER IN 2008-2016

Background and objectives. Prostate cancer is the second most common cancer diagnosis made in men. Given that 2,293,818 new cases are expected worldwide by 2040, it is important to conceptualize the disease and primary stage of cancer, distant metastases, testosterone concen­tration, and previous treatments help to understand and predict this disease.

The aim of the study is to determine the impact of pro­gnostic factors, comorbidities and systematic treatment on the survival of patients with metastatic prostate cancer.

Material and Methods. It is a retrospective analysis of data from 76 patients treated for metastatic prostate cancer (C61) at the Afiliate of Lithuanian University of Health Sciences Kaunas Oncology Hospital between 2008 and 2016. The following data were collected: age of patients, date of diagnosis, clinical stage of diagno­sis (cTNM), baseline PSA level (at diagnosis), Gleason score, treatment method used, localization of metastases, the period during which resistance to hormonal therapy developed, date of death. The date of diagnosis was con­sidered to be the date on which the prostate carcinoma was confirmed by histological examination. The data obtained in the study were analyzed using the programs IBM SPSS v28.0.

Results. A statistically significant correlation was found between the dependence of patient survival time and tumor differentiation grade (p=0.041) , the Charlson Comorbidity Index (p<0,001), treatment method used in prostate cancer unresponsive to hormone therapy (p=0.049), location of metastases (p=0.021), the time during which resistance to hormone therapy developed (p<0.001).

Conclusions. The risk of dying from prostate cancer de­pends on the period during which resistance to hormone therapy has developed and the Charlson comorbidity index. The higher the Charlson comorbidity index, the lower the survival rate. In patients with hormone-sen­sitive prostate cancer, the choice of treatment does not affect survival, and in patients with hormone-resistant prostate cancer, survival is prolonged by treatment with abiraterone acetate.